

Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease

Joseph Pierre Aboumsallem, PhD; Javid Moslehi, MD, PhD; Rudolf A. de Boer, MD, PhD

Overwhelming epidemiological evidence demonstrate that cardiovascular disease and cancer represent major health burdens in the United States, and they are the leading causes of mortality.¹ According to the National Center for Health Statistics and the Centers for Disease Control and Prevention, 616 828 of a total 2 471 984 deaths were caused by cardiovascular disease and another 134 148 were caused by cerebrovascular disease.² Numbers from the American Cancer Society reveal that \approx 17 million Americans have a history of cancer³ (representing 5% of the total US population) and \approx 1.7 million new cases are predicted to be diagnosed in 2019. Moreover, \approx 660 880 Americans are expected to die of cancer during 2019, which corresponds to 1660 deaths per day.⁴ Undoubtedly, these numbers will further increase as the population ages.

Generally, cardiovascular disease and cancer are viewed as 2 distinct disease entities. The appreciation that cancer and the cardiovascular disease may coincide mostly comes from cardiologists who care for patients with cardiovascular disease because of anticancer treatments (cardio-oncologists).^{5,6} Other examples where cancer and cardiovascular disease meet are cardiac neoplasm or when cancer itself causes cardiovascular disease, but these are less common. The substantial increase in the number of cancer survivors and the spectacular increase in new cancer therapies, often causing cardiovascular complications, resulted in the foundation of a new discipline called cardio-oncology.^{7,8} This subspecialty of cardiology establishes primary and secondary

risk approaches through surveillance as well as interventions to stratify and diminish cardiovascular risk, to preclude cardiovascular toxicity and its progression, and to manage the adverse effects of anticancer treatments.^{7,8}

Less appreciated are potential links between existing cardiovascular disorders and subsequent malignancy, demonstrating that patients with cardiovascular disease have higher cancer risk compared with individuals from the general population. Consequently, “reverse cardio-oncology” has started to attract more attention and called for awareness among physicians for the increased cancer risk in patients with cardiovascular disease.^{9–12} It has been suggested that these 2 disease entities share mutual risk factors, such as obesity, diabetes mellitus, alcoholism, and tobacco, which may explain, at least in part, concurrent manifestation.^{1,11,12} In addition, numerous ancillary mechanisms and pathways associated with cardiovascular disease were shown to be involved in cancer pathogenesis. Hence, further studies are needed to confirm and characterize the shared pathophysiological pathways between cardiovascular disease and cancer.^{9,11,12} As for now, clinicians should be aware of the increased risk and establish recommendations and guidelines for early diagnosis of malignancy, also and maybe even stronger so among patients with cardiovascular disease.

This review focuses on reverse cardio-oncology and highlights clinical studies, meta-analyses, and cohorts that have evaluated cancer risk in patients with cardiovascular disease and the risk associated with treatments of cardiovascular disease. In addition, this article summarizes mechanisms of actions that mediate the cross talk between cancer and cardiovascular disease.

Incidence of Cancer in Patients With Cardiovascular Diseases

The association between cardiovascular disease and cancer is not a novel concept.^{11–13} In the past few decades, numerous studies have reported connections between cancer and hypertension, thromboembolism/stroke, atrial fibrillation (AF), atherosclerotic cardiovascular disease, myocardial infarction, and heart failure. Nevertheless, most evidence

From the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (J.P.A., R.A.d.B.); Division of Cardiovascular Medicine, Clinical Pharmacology, Cardio-Oncology Program (J.M.), and Division of Oncology (J.M.), Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN.

Correspondence to: Rudolf A. de Boer, MD, PhD, Department of Cardiology, University Medical Center Groningen, AB31, PO Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: r.a.de.boer@umcg.nl

J Am Heart Assoc. 2020;9:e013754. Doi: 10.1161/JAHA.119.013754.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

stems from retrospective analyses with mostly noncausal relationships. In addition, available evidence could be skewed toward positive associations caused by publication bias. Because of the potential implications of this concept for clinicians, and its repercussions for patients with cardiovascular disease, the following section aims to summarize previous studies and to present a critical viewpoint of their findings.

Association Between Hypertension and Cancer Incidence

Several studies have hinted toward an association between hypertension and cancer incidence. A prospective cohort study showed that high blood pressure was associated with cancer incidence and cancer mortality, but this association was sturdier in men than in women.¹⁴ On the basis of 18 studies, a meta-analysis demonstrated a 1.6-fold increase in the risk of renal cell carcinoma in participants with hypertension.¹⁵ Another study reported a 5% and 7% higher risk for kidney cancer per every 10-mm Hg higher systolic blood pressure and diastolic blood pressure, respectively.¹⁶ Moreover, a positive correlation between hypertension and risk of colorectal cancer was estimated, with an 11% higher risk in individuals with hypertension.¹⁶ On the basis of a meta-analysis of 13 prospective studies, hypertension was linked to a 7% higher risk of total breast cancer.^{16,17} Association between hypertension and risk of prostate cancer was evaluated in a meta-analysis that used 21 cohort and case-control studies. Investigators reported a statistically significant 8% higher risk. However, this report did not take into account individual study design and quality.¹⁸ Furthermore, positive associations were observed between hypertension and risk of other cancers, including endometrial cancer, squamous cell carcinoma, esophageal adenocarcinoma, and liver cancer.¹⁶ However, these meta-analyses could not include a large number of prospective studies, and most of them were performed without comprehensive multivariable adjustments, which raises concerns about the validity of these findings. There have been additional meta-analyses for endometrial cancer, but their conclusions were shaped without taking into account the study design.^{19,20} Finally, no associations were observed between hypertension or blood pressure and risk of other cancers (namely, lung, cervix, brain, bladder, pancreas, stomach, and gallbladder).¹⁶

The safety of antihypertensive drugs with regard to cancer incidence has been debated. Many studies and meta-analyses have evaluated the carcinogenic potential of antihypertensive drugs. In the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), participants were randomly assigned to receive chlorthalidone (diuretic treatment), amlodipine (calcium channel blocker), or lisinopril (angiotensin-converting enzyme inhibitor). The investigators of

ALLHAT evaluated the clinical outcomes by antihypertensive treatment group and found that the 6-year rate of cancer was ≈ 10 per 100 people in the 3 groups. Also, cancer was the main noncardiovascular cause of death among patients treated with chlorthalidone, amlodipine, and lisinopril.²¹ Moreover, candesartan, an angiotensin receptor blocker tested for its effectivity in heart failure in the Candesartan Heart Failure Assessment of Reduction in Mortality and Morbidity program, has been linked to increased cancer risk. Of the 371 noncardiovascular deaths, 145 were cancer related. It was implied that death attributed to cancer was more frequent in the candesartan group.²² In contrast, other meta-analyses (comprising 70 randomized controlled trials) did not report any difference in cancer incidence and cancer mortality with antihypertensive treatments (ARBs [Angiotensin Receptor Blockers], angiotensin-converting enzyme inhibitors, β blockers, and diuretics) versus placebo. However, a slight increase in cancer risk was observed when angiotensin-converting enzyme inhibitor and ARB were administered together.²³ The inconsistencies between meta-analyses could be caused by bias, such as selection bias, which may lead to inaccurate deductions. Evaluating the link between antihypertensive treatments and cancer is critical, considering the difficulty of ruling out the effects of competing risks. Today, millions of patients with hypertension are treated with antihypertensive drugs. Therefore, antihypertensive medications and management require more consideration as they may influence cancer risk independent of hypertension or elevated blood pressures.

Cancer Prevalence Among Stroke Survivors and Patients With Thromboembolism

Many studies have reported a high prevalence of cancer deaths among patients who had a stroke.²⁴ The analyses of 3 large cohorts (the OSCP [Oxfordshire Community Stroke Project], the Lothian Stroke Register, and the IST [International Stroke Trial]) demonstrated that 38% of deaths were secondary to cancer.^{24,25} Furthermore, analyses of the data that were collected as part of the VISP (Vitamin Intervention for Stroke Prevention) study demonstrated a higher annual rate of age-adjusted cancer incidence among ischemic stroke survivors compared with those of the general population.²⁴ This increase was comparable to the slightly higher risk of cancer in patients with pulmonary embolism and venous thrombosis.^{26–28} Previously, the Swedish Inpatient Register was used to measure cancer incidence among 61 998 patients admitted to the hospital between the years 1965 and 1983 for venous thromboembolism. None of these patients had previously diagnosed cancer. The general conclusion was that venous thromboembolism could be a clear marker of cancer risk, and this assumption was based on the fact that 4% of cohort patients were diagnosed for

cancer at the time of the first admission, or during the first year.²⁸ Although several cohorts showed a continuous increase of cancer risk for as long as 10 years after the diagnosis of venous thromboembolism, others demonstrated a decline in cancer rates after 6 months. This inconsistency may be caused by the difference in cancer diagnosis strategies. Another explanation could be the size of the studies; some were larger, population based, and hospital record based, and others were smaller and observational.²⁹ Further research would be needed to evaluate the correlation between stroke or venous thromboembolism and cancer, and new guidelines should be established for cancer screening in diagnosed patients.

As for antithrombotic drugs, several studies have reported their antitumor benefits. Case-control studies suggested that the use of warfarin may be associated with a reduced incidence of urogenital malignancies.^{30,31} It is hypothesized that the potential antineoplastic effects of warfarin may be explained by its interaction with mediators of tumor invasion, such as tissue factor, factor VIIa, and urokinase receptors.²⁷ Furthermore, cancer was detected in 15.8% of patients who were treated for 6 weeks with oral anticoagulants and in 10.3% of patients who were treated for 6 months, but the investigators did not demonstrate the percentage of cancer among untreated participants.²⁷ Findings generated from another observational study showed that shorter duration of anticoagulation was associated with a higher cancer risk compared with longer duration of anticoagulant administration, which complements the previous findings.²⁹ Data from randomized trials were used to assess the effects of aspirin on risks of vascular and cancer events, according to dose and body weight. The administration of 75 to 100 mg of aspirin reduced risk of colorectal cancer in participants with a body weight <70 kg, but this reduction was not observed in people weighing ≥70 kg. However, with higher aspirin doses (≥325 mg), similar benefits were observed in individuals weighing up to 80 kg.³² Aspirin did not affect the total number of cancer deaths. Nevertheless, the investigators demonstrated that aspirin diminished cancer-related deaths, after 5 years of follow-up, in individuals weighing <70 kg. The ASPREE (Aspirin in Reducing Events in the Elderly) trial was conducted in the United States and Australia to assess the effect of aspirin on longevity and all-cause of mortality in healthy elderly individuals.³³ In total, 19 114 participants were randomly assigned to receive 100 mg aspirin or placebo. The investigators found that cancer was the main cause of death in both groups and reported a higher risk of cancer-related death in the aspirin group compared with the placebo group (6.7 versus 5.1 events per 1000 person-years). In addition, the percentages of cancer-death (cancer-death/all causes of death) were shown to be higher in the aspirin group in comparison to the placebo group (52.9% versus 46%).

These findings contradict the findings of previous meta-analyses in which aspirin was shown to have a protective effect on cancer-related mortality. It is still unclear whether aspirin has an early or delayed anticancer effect.³³ Maybe cancer physiological features and their molecular patterns differ among age and weight groups. It has been shown that aspirin could affect several aspects of cancer, such as inflammation, angiogenesis, metastasis, and tumor growth.³⁴ Further assessments are still needed to evaluate the mechanisms by which these drugs exert their anticancer effects.

AF: Is a Potential Risk Marker for Cancer

AF is the most common form of cardiac arrhythmia,^{35,36} and it is linked to other major cardiovascular complications.^{37–39} Patients with AF are exposed to a substantial risk of death because of noncardiovascular causes.⁴⁰ In 1994, the first report of AF preceding colon cancer was published.⁴¹ Twenty years later, the registry study of all Danish patients was published and showed that participants had a 2.5% absolute risk of cancer in the first 3 months after the diagnosis of AF.⁴² The investigators found that 57% of the cancer cases were metastatic at the time of diagnosis, which led them to conclude that AF, to some extent, may be regarded as a marker for occult cancer.⁴² The RE-LY (Randomized Evaluation Long-Term Anticoagulant Therapy Study) showed that more than one third of all deaths among participants with AF were caused by noncardiovascular reasons, and the malignant tumors were a main cause of these mortalities.^{40,43} Also, the relation between AF and cancer was inspected in the “WHS (Women’s Health Study)”,⁴³ which is a randomized clinical study that assessed the effects of low-dose aspirin and vitamin E in the primary prevention of cancer and cardiovascular diseases.^{44,45} The investigators found that 10% of participants with new-onset AF developed subsequent cancer.⁴³ Moreover, AF was substantially associated with cancer occurrence, and this correlation was not affected by the administration of aspirin nor by the administration of vitamin E.⁴³ The risk of cancer was notably higher in women with paroxysmal or nonparoxysmal AF. The multivariable-adjusted association between new-onset AF and colon cancer was statistically significant, but this was not the case for lung and breast cancers.⁴³ In 2018, a Danish population-based cohort study evaluated the correlation between AF and risk of cancer in 26 222 men and 28 879 women free of AF and cancer at baseline.⁴⁶ A total of 15% of men and 11.1% of women with new-onset AF had a subsequent cancer.⁴⁶ During the 12-year period after the diagnosis of AF, 23.3% of men and 19.1% of women were diagnosed with cancer. It was also noted that for both sexes, the incidence rate of any type of cancer (any type of cancer or lung and colorectal cancer) was higher during the first 3 months after the diagnosis of AF.⁴⁶

There were several attempts to solve the question as to whether AF can be considered as a risk factor for cancer. Considering the strength of this statement, one should keep in mind that the term “risk factor” refers to a causal connection between outcome and exposure. The mechanisms mediating these associations are perhaps multifactorial and comprise common risk factors and pathways.⁴⁷

The updated guidelines for the management of patients with AF, established by the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society, recommend the use of several anticoagulants, such as warfarin, dabigatran, rivaroxaban, and apixaban.⁴⁸ The RE-LY evaluated 2 fixed doses of dabigatran, which is a direct thrombin inhibitor. The doses were blindly administered, and with open-label use of warfarin in participants who had AF.⁴⁰ Data on mortality showed that 61.41% of deaths were because of cardiovascular causes and 13.93% were cancer-related deaths. Also, cancer was the number one noncardiovascular cause of death in the dabigatran and warfarin groups.⁴⁰ In the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), individuals with nonvalvular AF were randomized to rivaroxaban or dose-adjusted warfarin. Rivaroxaban and warfarin groups did not exhibit a significant difference in all-cause mortality. Once again, malignancy-related mortalities were the highest among the noncardiovascular mortalities in both groups.⁴⁹ The ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial randomized participants with AF to apixaban or warfarin. Apixaban was superior to warfarin in preventing stroke events, and also in showing less bleeding and lower mortality.⁵⁰ Also, malignancy was the most common cause of death among noncardiovascular deaths in the ARISTOTLE trial (21%).⁵¹ Considering the fact that cancer is the leading noncardiovascular cause of mortality in most of the trials, the safety of the drugs used for the management of AF should be assessed continuously to avoid any further health burden.

Cancer Prevalence in Patients With Atherosclerotic Cardiovascular Diseases and Myocardial Infarction

In the modern era, cardiac care in patients with atherosclerotic cardiovascular diseases has markedly improved.⁵² Invasive and pharmaceutical strategies, adopted by the long-term cardiovascular care systems, have resulted in a better prevention of atherosclerotic events and their complications.⁵³ Trends in causes of mortality in patients after percutaneous coronary interventions presented a shift from cardiovascular to noncardiovascular mortality in patients treated with percutaneous coronary intervention. This

increase in noncardiovascular mortality was attributed to cancer and other diseases.⁵⁴ On the basis of the ARIC (Atherosclerotic Risk in Communities) study, lower cancer prevalence could be linked to guidelines for the prevention of atherosclerosis, which means that there are many common risk factors for cancer and atherosclerotic cardiovascular alterations.⁵⁵ A total of 32 095 participants with cardiovascular diseases were enrolled in the SHIP (Sakakibara Health Integrative Profile) cohort study.⁵² To evaluate the incidence of cancer and mortality in patients with atherosclerosis, participants were segregated on the basis of the presence and absence of atherosclerotic cardiovascular diseases (namely, aortic diseases, coronary artery diseases, and peripheral artery diseases). Cancer prevalence (5% versus 2%) and mortality (6% versus 3%) were >2-fold higher in patients with atherosclerotic cardiovascular disease than in patients with nonatherosclerotic cardiovascular diseases.⁵² These findings suggest atherosclerosis as a risk factor for cancer and a marker of poor prognosis.⁵² Ultrasound and autopsy assessments demonstrated a strong correlation between atherosclerosis in the carotid and coronary arteries.^{56,57} Moreover, the incidence rates of cancer and death were evaluated in participants with myocardial infarction from data of 4 Danish registries: The Danish Civil Registration System registry, the NPR (Danish National Patient Registry), the National Causes of Death Registry, and the Danish National Prescription Registry.⁵⁸ All age groups showed that the prevalence rates of cancer and death were higher among participants with myocardial infarction.⁵⁸ The authors reported the highest incidence of cancer and death during the first year after the diagnosis of myocardial infarction. In addition, the youngest age group (30–54 years) exhibited the highest prevalence of colorectal, lung, and urinary track cancers. However, the risk of these cancers was decreased in older groups (55–69 and 70–99 years).⁵⁸ Recent study provided striking insights about the connection between myocardial infarction-induced heart failure and the intestinal tumor progression in C57BL/6J-ApcMin/J mice, which are predisposed to developing precancerous intestinal tumors.⁵⁹ Six weeks after the induction of myocardial infarction or the sham surgery, the investigators reported more and larger intestinal polyps in C57BL/6J-ApcMin/J mice with failing hearts.⁵⁹ At the cellular level, treating HT-29 with α -1-antichymotrypsin and α -1-antitrypsin, 2 proteins overexpressed in the myocardium of C57BL/6J-ApcMin/J mice with heart failure, resulted in an increased proliferation of these colorectal cancer cells.⁵⁹ Finally, the authors showed that heart failure and inflammation markers were associated with cancer incidence among participants with heart failure from the PREVENT (Prevention of Renal and Vascular End-Stage Disease) study.⁵⁹

There are many available antiatherosclerosis treatments, such as statins and antiplatelet agents.⁶⁰ The relation

between statins and cancer incidence is still under debate, although heavily studied. However, the anti-inflammatory properties of statins could be a starting point to evaluate any potential link with cancer prevention.¹¹ Revolution and advances in pharmacological treatments and percutaneous coronary intervention resulted in better disease management and significantly decreased mortality.^{61,62} In the United States, >85% of coronary stents used are drug-eluting stents.⁶³ In an integrated analysis on patients recruited in 4 trials,⁶⁴ patients were randomly assigned to receive a sirolimus-eluting or a bare-metal stent. Around 60% of deaths were caused by noncardiovascular causes, and cancer was among the most frequent noncardiovascular cause of death.⁶⁴ Moreover, a meta-analysis of 17 stent trials revealed that cancer, stroke, and infectious diseases were the main noncardiovascular causes of mortality.⁶⁵ These findings suggest a possible connection between stenting and cancer-related mortality and serve as a basis for further delineations.

To conclude, the epidemiological studies above present interesting evidence of associations between cardiovascular disease and the risk of incident cancer. Although these findings certainly raise significant scientific questions and are of considerable hypothesis-generating value, it is important to critically assess and highlight their limitations and validity. Most evidence originates from associations identified in retrospective analyses. This has inherent limitations in that causality is not guaranteed and that retrospective analyses are hampered by their original design not being powered toward specific cancer outcomes. In addition, the reported potential pro-cancer and anti-cancer effects of cardiovascular medication constitute contradictory information because the studies reporting them were not necessarily concordant with each other, even when the same treatment was being studied. As such, future targeted and independent studies are required before definitive conclusions can be drawn. Last, to eventually reach clinically relevant and applicable conclusions, translation of the shared risk factors and biological processes common to both cancer and cardiovascular disease to clinical significance is imperative.

Potential Mediators of the Cross Talk Between Cardiovascular Disease and Cancer

Apart from the above-mentioned potential epidemiological association, shared biological mechanisms and risk factors may explain the link between cardiovascular disease and cancer. Among others, pathways related to inflammation, clonal hematopoiesis, and hypoxia, as well as circulating microRNAs, extracellular vesicles, and mediators of cardiac origin are of interest in this regard. Advancements in our scientific understanding behind the interactions between cardiovascular disease and cancer and the exact role of all

the aforementioned factors in this cross talk could potentially lead to mechanistic insights that can guide future therapeutic research and clinical decision making. However, the unification of the available literature into a quintessential distilled essence poses considerable challenges, considering the heterogeneity and disparity of experimental designs, end points, and scientific messages of the available literature. Therefore, the following section aims to summarize current knowledge to bridge past and future research approaches.

Inflammation as a Key Mediator of the Pathophysiological Connection Between Cardiovascular Disease and Cancer

Inflammatory pathways contribute to the pathophysiological features of cardiovascular disease and cancer, and they are involved in the initiation, progression, and poor prognosis of the 2 diseases.⁶⁶ Recent studies emphasized the involvement of many inflammatory mediators in the EMT (epithelial to mesenchymal transition), which is as a key step toward malignant transformation and metastatic behavior.^{66,67} In the context of myocardial infarction, necrotic cells intensify inflammatory responses by releasing danger signals.⁶⁸ Downstream signaling comprises the overactivation of mitogen-activated protein kinases and the abnormal stimulation of the nuclear factor- κ B. Subsequent overexpression of proinflammatory genes (cytokines and chemokines) triggers inflammatory cells, causes oxidative damage and stress, causes DNA alterations, and modifies the tissue microenvironment, which can lead to malignant transformation in cells.⁶⁹ Ischemia induces several cytokines, including tumor necrosis factor, which is a potent activator of nuclear factor- κ B, a primary mediator of inflammation in cancer.^{70,71} Recently, the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) has reported promising results, validating inflammation as a worthwhile target for cardiovascular disease management.⁷² The investigators showed that canakinumab, an interleukin-1 β neutralizing monoclonal antibody, diminished cardiovascular events in treated participants.⁷³ Also, total cancer mortality and lung cancer fatalities were substantially lower in the canakinumab group than in the placebo group.⁷² In addition, it has been shown that heart failure-associated inflammatory markers, including C-reactive protein, had a clear predictive value independently of cancer risk factors.⁵⁹ The previously discussed α -1-antichymotrypsin is strongly related to systemic inflammation, and it is one of the proteins that were elevated in patients with heart failure.^{59,74,75} The same group showed that α -1-antichymotrypsin induces colorectal cancer cell (HT-29) proliferation and tumor growth via protein kinase B pathways. The investigators reported a significant phosphorylation of protein kinase B and ribosomal protein S6 in HT-29 treated with α -1-antichymotrypsin.⁵⁹ Assessing

inflammation as a mechanistic link between the 2 diseases could offer numerous opportunities and innovative solutions to reduce their heavy burden.

Clonal Hematopoiesis: A Newly Recognized Link Between Cardiovascular Disease and Cancer

Somatic genetic mutations are an unescapable consequence of aging.^{76,77} This is especially true in the highly proliferative hematopoietic tissues.⁷⁸ Genetic alterations in bone marrow hematopoietic stem cells result in the generation of mutated leukocyte clones in the peripheral blood.⁷⁹ This state is not cancer, but could be considered as a step toward leukemia, which leads to the term “clonal hematopoiesis of indeterminate potential” (CHiP). In fact, the transition to leukemia necessitates 2 or 3 consecutive mutations in cancer driver genes within the same clone.⁷⁹ Mutations in >20 genes have been shown to be involved in the transition to myelodysplastic syndrome and acute myeloid leukemia.⁷⁹ The analysis of bone marrow–derived mononuclear cells isolated from patients showed that somatic mutations in hematopoietic cells, particularly in the genes Ten-Eleven Translocation-2 (TET2) and DNA methyltransferase 3A, were associated with the development and poor prognosis of heart failure.⁸⁰ Another study found that mutations in TET2, Janus kinase 2, and additional sex combs-like were associated with early-onset myocardial infarction.⁸¹ The absence of the CHiP driver gene TET2 in mice resulted in accelerated atherosclerosis progression and higher predisposition to cardiac dysfunction.^{81,82} Experiments in murine models reported an elevated IL-1 β activity in the presence of CHiP mutations.^{81,83} Interestingly, dysfunctional TET2 was linked to the activation

of the cytoplasmic supramolecular assembly Nod-like receptor protein 3 inflammasome and inflammatory cytokine interleukin-6.^{84,85} It has been suggested that inflammatory mediators, like interleukin-1 β , could affect cardiovascular and oncological outcomes in individuals with CHiP.⁸⁶ The CANTOS revealed that canakinumab, an interleukin-1 β antibody, decreased cardiovascular incidence.⁸⁷ Interestingly, CHiP-positive patients (with TET2 mutations) in the CANTOS benefitted better to canakinumab than participants without CHiP.⁸⁸ In addition, the administration of higher dosages of canakinumab resulted in reduced lung cancer prevalence and less cancer mortality.⁷² Furthermore, Nod-like receptor protein 3 and interleukin-1 β can promote tumor growth and metastasis in several cancer types, such as breast cancer, lung cancer, and melanoma.⁸⁹ These findings suggest that CHiP is a new link between the 2 major diseases. The mechanisms that underlie this correlation include common mutations in the oncogenic genes and inflammatory factors secreted by the mutant leukocytes, as depicted in Figure 1. Currently, we have more questions than answers and further investigations are needed to identify the aspects of this correlation.

Hypoxia Caused by Cardiovascular Disease and Its Role in Cancer Progression

Hypoxia in patients with cardiovascular disease could be triggered by insufficient blood flow, hypoxemia, and microvascular-endothelial alterations.⁵ At the molecular level, hypoxia-inducible factor 1 is stabilized in response to myocardial ischemia or infarction.⁹⁰ Hypoxia-inducible factor 1 is a transcription factor that induces transcription of vascular




Figure 1. Graphic illustration showing somatic mutations in hematopoietic stem cells as a common path for cancer and cardiovascular disease.




Figure 2. Theoretical depiction of the mechanisms by which hypoxia contributes to cancer growth and angiogenesis. HIF-1 indicates hypoxia-inducible factor 1; VEGF, vascular endothelial growth factor.

endothelial growth factor and is involved in atherosclerosis progression.⁹¹ As discussed in another review,⁵ in the context of cancer, hypoxia-inducible factor 1 stimulates tumor growth and progression by increasing the expression of antiapoptotic factors and boosting angiogenesis.^{92–94} Besides, vascular endothelial growth factor is a key mediator of angiogenesis in cancer.⁹⁵ The pathogenesis of several cancer types, including multiple melanoma and breast cancer, involves numerous hypoxia-triggered pathways.^{96,97} Therefore, hypoxia-driven mechanisms stimulated by cardiovascular disease could result in malignancies, which makes them another significant therapeutic target (Figure 2).

Circulating Factors Linking Cardiovascular Disease to Cancer

Beside recognizing new biomarkers, it is essential to understand their function and evaluate the mechanisms by which they affect the homeostasis in tissues. Under pathological conditions, multiple cardiac cells, such as fibroblasts, cardiomyocytes, and smooth muscle cells, secrete “cardiokines” into the circulation (Figure 3).⁹⁸ Because of their endocrine and paracrine effects, the initiation and progression of many diseases could be mediated by these cardiac factors. In ischemic hearts, cardiomyocytes generate many cardiac factors, including Apelin.⁹⁹ The latter readapts actin cytoskeleton organization and increases the level of membrane type 1 matrix metalloprotease, which boosts proteolytic capacities and migration abilities in colon cancer cells.¹⁰⁰

After ischemia or reperfusion (ischemia-reperfusion injury), fibroblasts produce fibroblast growth factors to enhance cell survival and cardiac recovery.^{101,102} The fibroblast growth factor system mediates epithelial to mesenchymal transition and promotes tumor angiogenesis and progression.¹⁰³ Furthermore, ventricular hypertrophy is strongly associated with the production of another cardiokine, called osteopontin, which is mainly produced by cardiomyocytes.¹⁰⁴ As demonstrated in another review, osteopontin has been shown to promote the development of many solid organ tumors via different pathways.¹⁰⁵ Atherosclerotic carotid plaques secrete growth arrest-specific gene 6, which stimulates survival and mobility of vascular smooth muscle cells and promotes their accumulation in the atherosclerotic plaque.¹⁰⁶ On the basis of in vitro studies, growth arrest-specific gene 6 promotes EMT and cancer invasiveness by activating mitogen-activated protein kinase and Slug pathways.¹⁰⁷ Under hemodynamic stress, cardiomyocytes secrete atrial natriuretic peptide.¹⁰⁸ In contrast to the other cardiokines discussed in this review, atrial natriuretic peptide has been demonstrated to have anticancer effects by targeting many signaling pathways, such as c-FOS and c-JUN, rat sarcoma, mitogen protein kinase 1/2, and extracellular signal-regulated kinases 1/2.¹⁰⁸ In addition to cardiokines, the cardiovascular system secretes other factors and genetic materials, such as microRNAs.

To date, circulating microRNAs have been identified as biomarkers for diagnostic and prognostic purposes.¹⁰⁹ MicroRNAs modulate a variety of cellular and biological processes, including cell proliferation, apoptosis, stemness, senescence, epithelial to mesenchymal transition, and inflammation.¹¹⁰ Therefore, microRNAs are involved in the pathogenesis of many human diseases, such as heart diseases,¹¹¹ vascular diseases,¹¹² and cancers.¹¹³ In a context-dependent manner, the same microRNAs can function as a cardio-microRNA, angi-microRNA, or onco-microRNA.¹¹⁰ On the basis of previous experimental screening of microRNA reports and validation techniques using next-generation sequencing, 4 microRNAs were identified as cardio-microRNAs as they were upregulated in human heart disease, and they were as follows: microRNA-24, microRNA-125b, microRNA-195, and microRNA-214.^{114–118} Interestingly, the same 4 microRNAs were reported as oncogenic or tumor suppressors in several cancer subtypes, including myeloid leukemia, pancreatic cancer, lung adenocarcinoma, and prostate cancer.¹¹⁰ Therefore, cardio-microRNAs are potential connectors between cardiovascular disease and tumors, which makes them central therapeutic targets. Establishing databases of circulating microRNAs from cancer and cardiovascular disease is required to bridge the gap between the 2 fields. The circulating microRNAs could be conjugated with the high-density lipoprotein and Argonaute 2 protein or transported within extracellular vesicles (exosomes and microvesicles) (Figure 3).^{119–122}

In terms of contents, extracellular vesicles are loaded with distinct components of lipids (phospholipids), proteins (membrane receptors, enzymes, regulatory proteins, and adhesion molecules), genetic material (nucleic acids, mRNAs, and microRNAs), cytokines, chemokines, and growth factors.¹²³ Extracellular vesicles and their contents are a rapidly growing area of research in cancer because of their contribution to oncogenesis, cancer invasiveness, epithelial to mesenchymal transition, and metastasis, and resistance to anticancer chemotherapy.¹²⁴ Extracellular vesicles involved in cardiovascular diseases share features with the ones that mediate cancer progression and development (Figure 3).¹²⁴ The study by Ohtsuka and colleagues demonstrated that platelet-derived microvesicles, obtained from atherosclerotic patients, promote neovascularization by secreting the regulated upon activation normal T-cell expressed and secreted.¹²⁵ The latter was already demonstrated to be involved in gastric cancer metastasis.¹²⁶ Regulated upon activation normal T-cell expressed and secreted may contribute to breast cancer progression by promoting monocyte migration into tumor sites. Also, regulated upon activation normal T-cell expressed and secreted induces the expression of matrix metalloproteinase 9 and stimulates vascularity.¹²⁷ These data indicate that extracellular vesicles constitute another connector between cardiovascular disease and cancer. Detecting, analyzing, and validating the content and the features of extracellular vesicles are required to reach an effective therapeutic application of these particles into the clinical field.

Clinical Implications

Clinical trial data, meta-analyses, and cohort studies consistently confirmed the correlation between cardiovascular disease and cancer. This serves as a basis for further investigations to understand mechanisms that mediate this connection and to identify new therapeutic targets. In the next few years, we expect that the field of cardio-oncology will evolve in innovative ways with breakthroughs that will translate into their use for diagnosis, primary prevention, treatment, and other clinically relevant end points (Figure 4).

However, inconsistencies between the outcomes of the published studies are a limitation, and generation of more high-quality data is needed. The apparent discrepancies may be caused by differences in cancer and cardiovascular diagnoses, guidelines, and strategies. Another reason could be the size and design of the various studies. Besides, cancer and cardiovascular disease are general terms that refer to large groups of heterogeneous diseases, which complicates analyses and interpretations of data. Unifying inclusion criteria, using stronger diagnostic guidelines, and performing meticulous end point adjudication will help to improve the quality of generated data. Also, clinical data registries should be established in more countries to provide tailored outcomes based on the characteristics of each population.

Clearly, intense collaborations between oncologists, hematologists, and cardiovascular specialists will be required to establish guidelines for cardio-oncology and reverse cardio-oncology. For instance, the study of CHIP detection involves




Figure 3. Theoretical depiction of cardiac secretome and its effect on tumor development, mobility, and metastasis.

expensive DNA sequencing techniques and stand-alone initiatives but will be costly and likely not feasible. However, in the near future, decreased cost of CHIP testing would allow screening of more individuals, furthering research and collaboration efforts.⁷⁹ In addition to clinical data, we anticipate that identifying and measuring biomarkers will be essential to establish clinical prediction models and algorithms to evaluate the risk of cancer among patients with cardiovascular diseases. Moreover, the use of cardiovascular disease drugs requires more attention as it may impact cancer risk independent of cardiovascular disease. Accordingly, health-care professionals should modify cardiovascular disease management guidelines and establish primary and secondary risk approaches through surveillance as well as interventions in a concerted effort to reduce cancer risk, manage the adverse effects of cardiovascular treatments, and allow optimal cardiovascular and cancer outcomes.

In summary, although classic cardio-oncology focuses on cardiovascular risk in patients with current or treated cancer, reverse cardio-oncology deals with inherent cancer risk in

patients with cardiovascular disease. Recent data have raised more awareness for this phenomenon. Shared risk factors, pathophysiological pathways, and treatments may explain the complex relation. Future studies should ensure precise phenotyping of both disease domains and help to identify risk assessment and treatment algorithms for patients.

Sources of Funding

Dr de Boer is supported by the European Research Council (CoG 818715 and SECRETE-HF); and further by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40; CVON SHE-PREDICTS-HF, grant 2017-21; CVON RED-CVD, grant 2017-11; and CVON PREDICT2, grant 2018-30); the Innovative Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350); and by a grant from the leDucq Foundation (Cure Phospholamban Induced Cardiomyopathy). Dr Moslehi is supported by National Institutes of Health grants R56 141466 and R01 141466.




Figure 4. Illustration of the reverse cardio-oncology clinical end points. CHIP indicates clonal hematopoiesis of indeterminate potential; CVD, cardiovascular disease.

Disclosures

The UMCG (University Medical Center Groningen), which employs Dr de Boer, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk, and Roche. Dr de Boer received personal fees from Abbott, AstraZeneca, MandalMed Inc, and Novartis.

Dr Moslehi is a consultant for Pfizer, Novartis, Bristol Myers Squibb, Takeda, Audentes, Intrexon, Nektar, and Deciphera. The remaining author has no disclosures to report.

References

- Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. *Circulation*. 2016;133:1104–1114.
- Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. *Circulation*. 2013;127:749–756.
- American Cancer Society. *Cancer Treatment & Survivorship Facts & Figures 2019–2021*. Atlanta, GA: American Cancer Society; 2019.
- American Cancer Society. *Cancer Facts & Figures 2019*. Atlanta, GA: American Cancer Society; 2019.
- Hasin T, Iakobishvili Z, Weisz G. Associated risk of malignancy in patients with cardiovascular disease: evidence and possible mechanism. *Am J Med*. 2017;130:780–785.
- Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. *N Engl J Med*. 2016;375:1457–1467.
- Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37:2768–2801.
- Moslehi J, Fujiwara K, Guzik T. Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need. *Cardiovasc Res*. 2019;115:819–823.
- Coviello JS. Cardiovascular and cancer risk: the role of cardio-oncology. *J Adv Pract Oncol*. 2018;9:160–176.
- van Kruijsdijk RC, van der Graaf Y, Peeters PH, Visseren FL; Second Manifestations of Adsg. Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. *Cancer Epidemiol Biomarkers Prev*. 2013;22:1267–1277.
- Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. *Cardiovasc Res*. 2019;115:844–853.
- de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. *Eur J Heart Fail*. 2019 Jul 18. [Epub ahead of print]. Available at: <https://onlinelibrary.wiley.com/doi/full/10.1002/ehfj.1539>. Accessed October 22, 2019.
- Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer. *Circulation*. 2018;138:735–742.
- Stocks T, Van Hemelrijck M, Manjer J, Borge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G, Tretli S, Concin H, Engeland A, Jonsson H, Stattin P. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. *Hypertension*. 2012;59:802–810.
- Corrao G, Scotti L, Bagnardi V, Sega R. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. *Curr Drug Saf*. 2007;2:125–133.
- Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez DS, Ntzani EE, Tsilidis KK. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. *Sci Rep*. 2019;9:8565.
- Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, He J. Hypertension and breast cancer risk: a systematic review and meta-analysis. *Sci Rep*. 2017;7:44877.
- Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, Ji A, Zhu Y, Xu X, Zheng X, Xie L. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. *Sci Rep*. 2016;6:31358.
- Aune D, Sen A, Vatten LJ. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. *Sci Rep*. 2017;7:44808.
- Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. *Endocrine*. 2014;45:28–36.
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288:2981–2997.
- Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation*. 2004;110:2180–2183.
- Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Watterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. *Lancet Oncol*. 2011;12:65–82.
- Qureshi AI, Malik AA, Saeed O, Adil MM, Rodriguez GJ, Suri MF. Incident cancer in a cohort of 3,247 cancer diagnosis free ischemic stroke patients. *Cerebrovasc Dis*. 2015;39:262–268.
- Slot KB, Berge E, Sandercock P, Lewis SC, Dorman P, Dennis M; Oxfordshire Community Stroke Project; Lothian Stroke Register; International Stroke Trial (UK). Causes of death by level of dependency at 6 months after ischemic stroke in 3 large cohorts. *Stroke*. 2009;40:1585–1589.
- Sorensen HT, Mellekjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. *N Engl J Med*. 1998;338:1169–1173.
- Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of Anticoagulation Trial. *N Engl J Med*. 2000;342:1953–1958.
- Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. *Lancet*. 1998;351:1077–1080.
- Eischer L, Kammer M, Traby L, Kyrle PA, Eichinger S. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study. *J Thromb Haemost*. 2017;15:1368–1374.
- Blumentals WA, Foulis PR, Schwartz SW, Mason TJ. Does warfarin therapy influence the risk of bladder cancer? *J Thromb Haemost*. 2004;9:1801–1805.
- Tagalakis V, Tamim H, Blostein M, Collet JP, Hanley JA, Kahn SR. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. *Lancet Oncol*. 2007;8:395–402.
- Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. *Lancet*. 2018;392:387–399.
- McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group. Effect of aspirin on all-cause mortality in the healthy elderly. *N Engl J Med*. 2018;379:1519–1528.
- Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. *Med Res Rev*. 2019;39:114–145.
- Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285:2370–2375.
- Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur Heart J*. 2013;34:2746–2751.
- Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation*. 1998;98:946–952.
- Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, Albert CM. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. *JAMA*. 2011;305:2080–2087.
- Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. *J Am Coll Cardiol*. 2002;40:1636–1644.
- Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Causes of death and influencing factors in patients with atrial

- fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. *Circulation*. 2013;128:2192–2201.
41. Muller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer: a case-control study among veterans. *Dig Dis Sci*. 1994;39:2480–2484.
 42. Ostefeld EB, Erichsen R, Pedersen L, Farkas DK, Weiss NS, Sorensen HT. Atrial fibrillation as a marker of occult cancer. *PLoS One*. 2014;9:e102861.
 43. Conen D, Wong JA, Sandhu RK, Cook NR, Lee IM, Buring JE, Albert CM. Risk of malignant cancer among women with new-onset atrial fibrillation. *JAMA Cardiol*. 2016;1:389–396.
 44. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. *J Womens Health Gen Based Med*. 2000;9:19–27.
 45. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*. 2005;352:1293–1304.
 46. Vinter N, Christesen AMS, Fenger-Gron M, Tjonneland A, Frost L. Atrial fibrillation and risk of cancer: a Danish population-based cohort study. *J Am Heart Assoc*. 2018;7:e009543. DOI: 10.1161/JAHA.118.009543.
 47. Rahman F, Ko D, Benjamin EJ. Association of atrial fibrillation and cancer. *JAMA Cardiol*. 2016;1:384–386.
 48. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2019;74:104–132.
 49. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. *J Am Heart Assoc*. 2016;5:e002197. DOI: 10.1161/JAHA.115.002197.
 50. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365:981–992.
 51. Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of biomarkers to predict specific causes of death in patients with atrial fibrillation. *Circulation*. 2018;138:1666–1676.
 52. Suzuki M, Tomoike H, Sumiyoshi T, Nagatomo Y, Hosoda T, Nagayama M, Ishikawa Y, Sawa T, Iimuro S, Yoshikawa T, Hosoda S. Incidence of cancers in patients with atherosclerotic cardiovascular diseases. *Int J Cardiol Heart Vasc*. 2017;17:11–16.
 53. Steg PG, Cheong AP. Death (after percutaneous coronary intervention) is no longer what it used to be. *Circulation*. 2014;129:1267–1269.
 54. Spoon DB, Psaltis PJ, Singh M, Holmes DR Jr, Gersh BJ, Rihal CS, Lennon RJ, Moussa ID, Simari RD, Gulati R. Trends in cause of death after percutaneous coronary intervention. *Circulation*. 2014;129:1286–1294.
 55. Rasmussen-Torvik LJ, Shay CM, Abramson JG, Friedrich CA, Nettleton JA, Prizment AE, Folsom AR. Ideal cardiovascular health is inversely associated with incident cancer: the Atherosclerosis Risk In Communities study. *Circulation*. 2013;127:1270–1275.
 56. Young W, Gofman JW, Tandy R, Malamud N, Waters ES. The quantitation of atherosclerosis. II: quantitative aspects of the relationship of blood pressure and atherosclerosis. *Am J Cardiol*. 1960;6:294–299.
 57. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR III. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. *Arterioscler Thromb*. 1991;11:1786–1794.
 58. Malmberg M, Christiansen CB, Schmiegelow MD, Torp-Pedersen C, Gislason G, Schou M. Incidence of new onset cancer in patients with a myocardial infarction—a nationwide cohort study. *BMC Cardiovasc Disord*. 2018;18:198.
 59. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Sillje HHW, de Boer RA. Heart failure stimulates tumor growth by circulating factors. *Circulation*. 2018;138:678–691.
 60. Maranhao RC, Leite AC Jr. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease. *Curr Pharm Des*. 2015;21:1196–1204.
 61. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet*. 2003;361:13–20.
 62. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. *J Am Coll Cardiol*. 2006;48:1319–1325.
 63. Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. *J Am Coll Cardiol*. 2005;45:1206–1212.
 64. Holmes DR Jr, Moses JW, Schofer J, Morice MC, Schampaert E, Leon MB. Cause of death with bare metal and sirolimus-eluting stents. *Eur Heart J*. 2006;27:2815–2822.
 65. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. *Eur Heart J*. 2006;27:2784–2814.
 66. Libby P, Kobold S. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases—expanding the concept of cardio-oncology. *Cardiovasc Res*. 2019;115:824–829.
 67. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. *Science*. 2011;331:1559–1564.
 68. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. *Nat Rev Cardiol*. 2011;8:292–300.
 69. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation—therapeutic opportunities and pharmacological challenges. *Pharmacol Rev*. 2013;65:47–89.
 70. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. *Front Biosci*. 2008;13:5094–5107.
 71. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood*. 2012;119:651–665.
 72. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;390:1833–1842.
 73. Aday AW, Ridker PM. Antiinflammatory therapy in clinical care: the CANTOS trial and beyond. *Front Cardiovasc Med*. 2018;5:62.
 74. Bode JG, Albrecht U, Haussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins—regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. *Eur J Cell Biol*. 2012;91:496–505.
 75. Surinova S, Choi M, Tao S, Schuffler PJ, Chang CY, Clough T, Vysloulzil K, Khoylou M, Srovnal J, Liu Y, Matondo M, Huttenhain R, Weisser J, Buhmann JM, Hajdudich M, Brenner H, Vittek O, Aebbersold R. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. *EMBO Mol Med*. 2015;7:1166–1178.
 76. Forsberg LA, Gisselsson D, Dumanski JP. Mosaicism in health and disease—clones picking up speed. *Nat Rev Genet*. 2017;18:128–142.
 77. Vij J. Somatic mutations, genome mosaicism, cancer and aging. *Curr Opin Genet Dev*. 2014;26:141–149.
 78. Fuster JJ, Walsh K. Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. *Circ Res*. 2018;122:523–532.
 79. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, Zeiher A, Jaiswal S, Schulz C, Blankstein R, Bolton KL, Steensma D, Levine RL, Ebert BL. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. *J Am Coll Cardiol*. 2019;74:567–577.
 80. Dorsheimer L, Assmus B, Rasper T, Ortman CA, Ecker A, Abou-El-Ardat K, Schmid T, Brune B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher AM, Rieger MA. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. *JAMA Cardiol*. 2019;4:25–33.
 81. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med*. 2017;377:111–121.
 82. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andres V, Hirschi KK, Martin KA, Walsh K. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science*. 2017;355:842–847.
 83. Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA, Yoshiyama M, Goukassian D, Cooper MA, Fuster JJ, Walsh K. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome. *J Am Coll Cardiol*. 2018;71:875–886.

84. Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. *J Am Coll Cardiol*. 2017;70:2278–2289.
85. Libby P, Jaiswal S, Lin AE, Ebert BL. CHIPPING away at the pathogenesis of heart failure. *JAMA Cardiol*. 2019;4:5–6.
86. Calvillo-Arguelles O, Jaiswal S, Shlush LI, Moslehi JJ, Schimmer A, Barac A, Thavandiranathan P. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. *JAMA Cardiol*. 2019;4:380–387.
87. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119–1131.
88. Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, D'Aco K, Fernandez A, Wache-Mainier C, Ridker PM, Beste MT, Basson CT. Abstract 15111: TET2-driven clonal hematopoiesis predicts enhanced response to canakinumab in the CANTOS trial: an exploratory analysis. 2018. Available at: https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.15111z.
89. Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. *Mol Cancer*. 2018;17:158.
90. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. *N Engl J Med*. 2000;342:626–633.
91. Gao L, Chen Q, Zhou X, Fan L. The role of hypoxia-inducible factor 1 in atherosclerosis. *J Clin Pathol*. 2012;65:872–876.
92. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. *Intern Med*. 2002;41:79–83.
93. Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. *Transl Res*. 2015;165:641–650.
94. Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CT, Poellinger L, Ong ST. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. *Blood*. 2014;123:3316–3326.
95. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. *Oncology*. 2005;69(suppl 3):4–10.
96. Nagelkerke A, Mujcic H, Bussink J, Wouters BG, van Laarhoven HW, Sweep FC, Span PN. Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. *Cancer*. 2011;117:3670–3681.
97. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. *Blood*. 2012;119:5782–5794.
98. Doroudgar S, Glembofski CC. The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart. *Trends Mol Med*. 2011;17:207–214.
99. Ronkainen VP, Ronkainen JJ, Hanninen SL, Leskinen H, Ruas JL, Pereira T, Poellinger L, Vuolteenaho O, Tavi P. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. *FASEB J*. 2007;21:1821–1830.
100. Podgorska M, Pietraszek-Gremplewicz K, Nowak D. Apelin effects migration and invasion abilities of colon cancer cells. *Cells*. 2018;7:E113.
101. Palmen M, Daemen MJ, De Windt LJ, Willems J, Dassen WR, Heeneman S, Zimmermann R, Van Bilsen M, Doevendans PA. Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism. *J Am Coll Cardiol*. 2004;44:1113–1123.
102. Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK, Cattini PA. Fibroblast growth factor-2 and cardioprotection. *Heart Fail Rev*. 2007;12:267–277.
103. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. *Curr Cancer Drug Targets*. 2009;9:639–651.
104. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. *Circulation*. 1997;96:3063–3071.
105. Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, Eguchi S, Gu J, Ma D. The role of osteopontin in the progression of solid organ tumour. *Cell Death Dis*. 2018;9:356.
106. Clauser S, Meilhac O, Bieche I, Raynal P, Bruneval P, Michel JB, Borgel D. Increased secretion of Gas6 by smooth muscle cells in human atherosclerotic carotid plaques. *Thromb Haemost*. 2012;107:140–149.
107. Lee Y, Lee M, Kim S. Gas6 induces cancer cell migration and epithelial-mesenchymal transition through upregulation of MAPK and Slug. *Biochem Biophys Res Commun*. 2013;434:8–14.
108. Dewey CM, Spittler KM, Ponce JM, Hall DD, Grueter CE. Cardiac-secreted factors as peripheral metabolic regulators and potential disease biomarkers. *J Am Heart Assoc*. 2016;5:e003101. DOI: 10.1161/JAHA.115.003101.
109. Ojha R, Nandani R, Pandey RK, Mishra A, Prajapati VK. Emerging role of circulating microRNA in the diagnosis of human infectious diseases. *J Cell Physiol*. 2019;234:1030–1043.
110. Katoh M. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. *Front Cell Dev Biol*. 2014;2:61.
111. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. *Circ Res*. 2008;103:1072–1083.
112. Wang S, Olson EN. AngiomiRs—key regulators of angiogenesis. *Curr Opin Genet Dev*. 2009;19:205–211.
113. Croce CM. Causes and consequences of microRNA dysregulation in cancer. *Nat Rev Genet*. 2009;10:704–714.
114. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc Natl Acad Sci USA*. 2006;103:18255–18260.
115. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB, Dorn GW II. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. *Circulation*. 2009;119:1263–1271.
116. Naga Prasad SV, Duan ZH, Gupta MK, Surampudi VS, Volinia S, Calin GA, Liu CG, Kotwal A, Moravec CS, Starling RC, Perez DM, Sen S, Wu Q, Plow EF, Croce CM, Karnik S. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. *J Biol Chem*. 2009;284:27487–27499.
117. Zhu X, Wang H, Liu F, Chen L, Luo W, Su P, Li W, Yu L, Yang X, Cai J. Identification of micro-RNA networks in end-stage heart failure because of dilated cardiomyopathy. *J Cell Mol Med*. 2013;17:1173–1187.
118. Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, Silva GJ, Heymans S, Cuppen E, Berezikov E, De Windt LJ, da Costa Martins P. A deep sequencing approach to uncover the miRNOME in the human heart. *PLoS One*. 2013;8:e57800.
119. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol*. 2008;110:13–21.
120. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB. Detection of microRNA expression in human peripheral blood microvesicles. *PLoS One*. 2008;3:e3694.
121. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol*. 2011;13:423–433.
122. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci USA*. 2011;108:5003–5008.
123. Badimon L, Suades R, Arderiu G, Pena E, Chiva-Blanch G, Padro T. Microvesicles in atherosclerosis and angiogenesis: from bench to bedside and reverse. *Front Cardiovasc Med*. 2017;4:77.
124. Shah R, Patel T, Freedman JE. Circulating extracellular vesicles in human disease. *N Engl J Med*. 2018;379:2180–2181.
125. Ohtsuka M, Sasaki K, Ueno T, Seki R, Nakayoshi T, Koiwaya H, Toyama Y, Yokoyama S, Mitsutake Y, Chibana H, Itaya N, Okamura T, Imaizumi T. Platelet-derived microparticles augment the adhesion and neovascularization capacities of circulating angiogenic cells obtained from atherosclerotic patients. *Atherosclerosis*. 2013;227:275–282.
126. Cao Z, Xu X, Luo X, Li L, Huang B, Li X, Tao D, Hu J, Gong J. Role of RANTES and its receptor in gastric cancer metastasis. *J Huazhong Univ Sci Technolog Med Sci*. 2011;31:342–347.
127. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of pro-migratory activity. *Cancer Res*. 2002;62:1093–1102.

Key Words: biomarker • cancer • cardiovascular disease • cardio-oncology • cardiokines • inflammation • reverse cardio-oncology • risk factor • somatic mutations